AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Prime Medicine, Inc. Common Stock (NASDAQ:PRME)
3.14 USD
-0.070 2.181%| Previous Close (in USD) | 3.21 |
|---|---|
| Change | -0.070 2.181% |
| 52 W H/L (in USD) | 17.200/4.110 |
| EBITDA (in USD) | -194.684M |
| PE Ratio | -- |
| Volume | 3359146 |
| Diluted Eps TTM | -2.05 |
| Total Assets (in USD) | 193.851M |
|---|---|
| Total Liabilities (in USD) | 60.78M |
| Revenue TTM (in USD) | 0.591M |
| Cash (in USD) | 41.574M |
| Market Cap (in USD) | 780.202 M |
| Revenue Per Share TTM | 0.006 |
| Gross Profit TTM (in USD) | -86.725M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Prime Medicine Inc. Common Stock
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.
Employees: 234
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Keith Michael Gottesdiener M.D. | Pres, CEO, Sec. & Director | 1954 |
| 2. | Dr. Ann L. Lee Ph.D. | Chief Technical Officer | 1962 |
| 3. | Dr. Jeremy S. Duffield M.D., Ph.D. | Chief Scientific Officer | 1968 |
| 4. | Dr. Andrew Anzalone M.D., Ph.D. | Co-Founder, Sr. Scientist II, Head of Prime Editing Platform & Head of Platform Devel. | 1986 |
| 5. | Dr. David R. Liu Ph.D. | Co-Founder & Chair of Scientific Advisory Board | NA |
| 6. | Ms. Carman Alenson CPA, M.B.A. | Chief Accounting Officer & Interim CFO | 1965 |
| 7. | Dr. Meredith Goldwasser | Sr. VP of Strategy & Corp. Operations and Head of Strategy & Corp. Operations | 1971 |
| 8. | Dr. Karen Brown J.D., Ph.D. | Sr. VP of Intellectual Property & Legal Affairs | NA |
| 9. | Ms. Niamh Alix | Chief HR Officer | NA |
| 10. | Mr. Richard Brudnick | Chief Bus. Officer | 1957 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Income Before Tax | -122.769M | -165.853M | -1.543M | - |
| Minority Interest | - | - | - | - |
| Net Income | -121.821M | -165.367M | -3.41M | - |
| Selling General Administrative | 29.819M | 13.924M | 3.162M | - |
| Gross Profit | 5.21M | - | 5.21M | - |
| Reconciled Depreciation | 2.224M | 0.568M | 0.043M | - |
| Ebit | -116.544M | -84.474M | -0.932M | -6.516M |
| Ebitda | -108.416M | -83.515M | -11.756M | - |
| Depreciation And Amortization | 8.128M | 0.959M | -10.824M | - |
| Operating Income | -116.544M | -84.474M | -0.932M | - |
| Other Operating Expenses | 116.544M | 84.474M | 6.142M | - |
| Interest Expense | 12.129M | 81.77M | 10.256M | - |
| Tax Provision | -0.948M | -0.486M | 1.867M | - |
| Interest Income | - | - | - | - |
| Net Interest Income | - | - | - | - |
| Income Tax Expense | -0.948M | -0.486M | 1.867M | 0.012M |
| Total Revenue | 5.21M | 0M | 5.21M | - |
| Total Operating Expenses | 116.544M | 84.474M | 6.142M | - |
| Cost Of Revenue | - | - | - | - |
| Total Other Income Expense Net | -6.225M | -81.379M | -0.611M | - |
| Net Income From Continuing Ops | -121.821M | -165.367M | -3.41M | - |
| Net Income Applicable To Common Shares | -142.014M | -184.119M | -5.055M | -8.382M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 193.851M | 360.314M | 301.856M | 54.783M | - |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 2.254M | 2.697M | 0.959M | 0.074M | - |
| Total Liab | 60.78M | 360.314M | 62.296M | 21.309M | - |
| Total Stockholder Equity | 133.071M | -293.581M | 239.56M | 33.474M | - |
| Other Current Liab | 1.605M | 10.688M | 12.299M | 19.192M | 6.77M |
| Common Stock | 0.002M | 0.002M | - | - | 0.001M |
| Capital Stock | 0.002M | 0.002M | 395.8M | 31.136M | - |
| Retained Earnings | -491.33M | -293.197M | -171.376M | -6.009M | -2.599M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 15.142M | 15.599M | 0.785M | - |
| Cash | 41.574M | 187.62M | 185.42M | 36.975M | - |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 56.423M | 26.714M | 57.983M | 19.442M | 7.308M |
| Current Deferred Revenue | 26.005M | - | 36.913M | - | - |
| Net Debt | -27.941M | -158.875M | -175.014M | -36.975M | - |
| Short Term Debt | 9.276M | 11.694M | 7.336M | - | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 13.633M | 28.745M | 10.406M | - | - |
| Other Stockholder Equity | 624.414M | -360.316M | 15.163M | 8.347M | - |
| Property Plant Equipment | - | 19.009M | 15.678M | 0.596M | - |
| Total Current Assets | 142.976M | 293.921M | 270.579M | 53.402M | 8.697M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 80.091M | 106.301M | 84.2M | 16.353M | - |
| Net Receivables | - | - | - | - | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 19.537M | 4.332M | 1.435M | 0.25M | - |
| Accumulated Other Comprehensive Income | -0.015M | -0.384M | -0.027M | - | - |
| Non Currrent Assets Other | 19.727M | -52.761M | 15.599M | 0.785M | - |
| Non Current Assets Total | 50.875M | 66.393M | 31.277M | 1.381M | - |
| Capital Lease Obligations | 13.633M | 28.745M | 10.406M | 0M | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Investments | -30.336M | -68.98M | -68.98M | -68.98M |
| Total Cashflows From Investing Activities | -47.096M | -73.626M | -1.062M | -1.062M |
| Total Cash From Financing Activities | 181.494M | 269.278M | 34.934M | 29.943M |
| Net Income | -121.821M | -165.367M | -3.41M | -7.587M |
| Change In Cash | 2.571M | 161.57M | 28.328M | 25.941M |
| Begin Period Cash Flow | 198.545M | 36.975M | 8.647M | - |
| End Period Cash Flow | 201.116M | 198.545M | 36.975M | 8.647M |
| Total Cash From Operating Activities | -131.827M | -34.082M | -5.544M | -4.002M |
| Depreciation | 2.224M | 0.568M | 0.043M | 0.043M |
| Other Cashflows From Investing Activities | -0.665M | -0.496M | -0.423M | -0.423M |
| Dividends Paid | - | - | - | - |
| Change To Inventory | - | - | - | - |
| Sale Purchase Of Stock | 181.494M | - | - | - |
| Other Cashflows From Financing Activities | -3.823M | 269.278M | 34.934M | -0.02M |
| Capital Expenditures | 16.095M | 4.15M | 0.639M | 0.639M |
| Change In Working Capital | -35.401M | 31.176M | 0.164M | - |
| Other Non Cash Items | 17.676M | 98.419M | -4.599M | - |
| Free Cash Flow | -147.922M | -38.232M | -6.183M | - |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | ARK Genomic Revolution ETF | 2 years ago | 3043384 |
| 2. | ARK Genomic Revolution | 2 years ago | 3013770 |
| 3. | ARK Disruptive Innovation Full Composite | 2 years ago | 2627665 |
| 4. | ARK Innovation ETF | 2 years ago | 2491779 |
| 5. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 2164971 |
| 6. | Vanguard Small Cap Index | 2 years ago | 1721698 |
| 7. | T. Rowe Price New Horizons | 2 years ago | 1631137 |
| 8. | US Small-Cap Growth II Equity Comp | 2 years ago | 1631137 |
| 9. | Nikko AM ARK Pstv Chg Innovt P JPY Acc | 2 years ago | 1470726 |
| 10. | Nikko AM ARK Disruptive Innovation A USD | 2 years ago | 1459267 |
| 11. | Vanguard Small Cap Growth Index Inv | 2 years ago | 972845 |
| 12. | iShares Russell 2000 ETF | 2 years ago | 937262 |
| 13. | T. Rowe Price Small-Cap Value | 2 years ago | 801678 |
| 14. | T. Rowe Price US Small-Cap Core Equity | 2 years ago | 742306 |
| 15. | T. Rowe Price Small-Cap Stock | 2 years ago | 742306 |
| 16. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 593826 |
| 17. | BlackRock Health Sciences Term Trust | 2 years ago | 412139 |
| 18. | Fidelity Small Cap Index | 2 years ago | 404809 |
| 19. | T. Rowe Price U.S. SC Value Eq Tr-Z | 2 years ago | 387579 |
| 20. | T. Rowe Price U.S. SC Core Eq Tr-Z | 2 years ago | 369926 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Alphabet Inc | 2 years ago | 15062498 |
| 2. | ARK Investment Management LLC | 2 years ago | 5993354 |
| 3. | Vanguard Group Inc | 2 years ago | 5801445 |
| 4. | FMR Inc | 2 years ago | 3925346 |
| 5. | BlackRock Inc | 2 years ago | 3778618 |
| 6. | Nikko Asset Management Americas Inc | 2 years ago | 3364663 |
| 7. | Sumitomo Mitsui Trust Holdings Inc | 2 years ago | 3364663 |
| 8. | T. Rowe Price Investment Management,Inc. | 2 years ago | 3090083 |
| 9. | T. Rowe Price Associates, Inc. | 2 years ago | 2522590 |
| 10. | Redmile Group, LLC | 2 years ago | 2074350 |
| 11. | Avidity Partners Management LP | 2 years ago | 1990000 |
| 12. | MWG Management Ltd. | 2 years ago | 1792210 |
| 13. | Baker Bros Advisors LP | 2 years ago | 1028466 |
| 14. | Geode Capital Management, LLC | 2 years ago | 887503 |
| 15. | State Street Corporation | 2 years ago | 759758 |
| 16. | Farallon Capital Management, L.L.C. | 2 years ago | 750000 |
| 17. | EcoR1 Capital, LLC | 2 years ago | 700000 |
| 18. | Greenwich Wealth Management LLC | 2 years ago | 578001 |
| 19. | Samsara BioCapital, LLC | 2 years ago | 540304 |
| 20. | Two Sigma Investments LLC | 2 years ago | 508078 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...